Want to see HK:9966 full AI Analyst Report?
9966 Stock Chart & Stats
HK$11.90
-HK$0.05(-1.46%)
At close: 4:00 PM EST
HK$11.90
-HK$0.05(-1.46%)
Day’s Range― - ―
52-Week RangeHK$6.23 - HK$15.75
Previous CloseN/A
Volume1.49M
Average Volume (3M)3.94M
Market Cap
HK$7.28B
Enterprise ValueHK$5.83B
Total Cash (Recent Filing)HK$1.35B
Total Debt (Recent Filing)HK$123.03M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding974,381,700
10 Day Avg. Volume3,868,184
30 Day Avg. Volume3,937,702
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)4.94
Price to Sales (P/S)15.34
P/FCF Ratio-55.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.38
Revenue Forecast (FY)HK$313.90M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA ~77% gross margin indicates advantaged product economics for antibody therapeutics. Durable high gross margins support operating leverage as sales scale, allow reinvestment into R&D or commercialization, and provide a buffer against variability in operating expenses over the medium term.
Low Financial LeverageA very low debt-to-equity ratio (~0.07) gives the company financial flexibility uncommon in biotech. This conservative leverage profile reduces near-term refinancing risk, preserves optionality to fund trials or commercial launches, and supports resilience through cash burn periods.
Integrated Oncology PlatformOwning capabilities from discovery through development, manufacturing and commercialization plus a focus on collaborations creates structural advantages. It enables value capture across stages, accelerates development via partners, and increases strategic paths to monetize successful assets long term.
Bears Say
Revenue VolatilityA ~30% revenue drop in 2025 signals volatile commercial performance or timing of milestones. Persistent top-line swings reduce visibility for planning R&D and commercial investment, complicate scaling economics, and increase probability of needing external funding over the medium term.
Return To Cash BurnOperating and free cash flow turned negative in 2025, creating renewed cash burn. Sustained negative cash generation heightens funding-risk, can force dilutive capital raises or expensive financing, and limits the firm's ability to pursue multiple trials or build commercial infrastructure simultaneously.
Reversion To Net LossesReverting to a ~111M net loss and steep EPS deterioration undermines the path to self-funding. Inconsistent profitability reflects either commercial execution or pipeline timing issues, weakening long-term cash generation prospects and increasing reliance on capital markets for sustained development.
Alphamab Oncology News
9966 FAQ
What was Alphamab Oncology’s price range in the past 12 months?
Alphamab Oncology lowest stock price was HK$6.23 and its highest was HK$15.75 in the past 12 months.
What is Alphamab Oncology’s market cap?
Alphamab Oncology’s market cap is HK$7.28B.
When is Alphamab Oncology’s upcoming earnings report date?
Alphamab Oncology’s upcoming earnings report date is Aug 20, 2026 which is in 11 days.
How were Alphamab Oncology’s earnings last quarter?
Alphamab Oncology released its earnings results on Mar 25, 2026. The company reported -HK$0.154 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.154.
Is Alphamab Oncology overvalued?
According to Wall Street analysts Alphamab Oncology’s price is currently Overvalued.
Does Alphamab Oncology pay dividends?
Alphamab Oncology does not currently pay dividends.
What is Alphamab Oncology’s EPS estimate?
Alphamab Oncology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alphamab Oncology have?
Alphamab Oncology has 974,381,700 shares outstanding.
What happened to Alphamab Oncology’s price movement after its last earnings report?
Alphamab Oncology reported an EPS of -HK$0.154 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.98%.
Which hedge fund is a major shareholder of Alphamab Oncology?
Currently, no hedge funds are holding shares in HK:9966
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alphamab Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
239.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.09%
Trailing 12-Months
Company Description
Alphamab Oncology
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
Technical Analysis
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
CStone Pharmaceuticals
―
Shanghai Henlius Biotech, Inc. Class H
―